Novartis Ag

Qun Jiang

Daniel J Poon

Keith Bruce Pfister

Qiong Zhang

Sabina Pecchi

Mika Lindvall

Jianguang Zhou

Wooseok Han

Xiaojing Michael Wang

Yue Pan

Vivek Rauniyar

Patrick Lee

Zhongcheng Min

Yu Ding

Zilin Huang

Jeffrey T Bagdanoff

Xiang Kou

Shejin Zhu

Xianming Jin

Lei Li

Thomas Ruch

Jeff Xianming Jin

Zhongbo Fei

Bin Li

Quanbing Wu

Like Chen

Chi Ming Cheung

Hao Wang

The present invention provides a process of synthesizing 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), or a salt thereof, or a solvate including hydrate thereof, and/or intermediates thereof, and the use of intermediates for preparing Compound X. In particular, the process relates to the preparation of Compound X using dynamic kinetic resolution (DKR) and asymmetric catalytic reduction, thereby providing an improved route to 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (Compound X) and compositions containing said compound, including the arginine salt, sodium salt and hydrated solid forms of Compound X.

Chemical process for manufacturing monobactam antibiotic and intermediates thereof

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

Aminoheteroaryl benzamides as kinase inhibitors

Growing community of inventors

Suzhou, Japan

Qun Jiang